According to latest analysis by Gen Consulting Company, the global idiopathic pulmonary fibrosis market is poised to grow by USD 2.0 billion during 2022-2028, progressing at a CAGR of 7.5% during the forecast period.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global idiopathic pulmonary fibrosis market. It traces the market's historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors' approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the idiopathic pulmonary fibrosis industry.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the drug type, action mode, end user, and region. The global market for idiopathic pulmonary fibrosis can be segmented by drug type: Nintedanib, Pirfenidone, others. The Nintedanib segment held the largest share of the global idiopathic pulmonary fibrosis market in 2021 and is anticipated to hold its share during the forecast period. Idiopathic pulmonary fibrosis market is further segmented by action mode: antifibrotic agent, tyrosine kinase inhibitor, other. Globally, the tyrosine kinase inhibitor segment made up the largest share of the idiopathic pulmonary fibrosis market. Based on end user, the idiopathic pulmonary fibrosis market is segmented into: hospital and clinic, others. The hospital and clinic segment was the largest contributor to the global idiopathic pulmonary fibrosis market in 2021. On the basis of region, the idiopathic pulmonary fibrosis market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America is estimated to account for the largest share of the global idiopathic pulmonary fibrosis market.
Market Segmentation
By drug type: Nintedanib, Pirfenidone, others
By action mode: antifibrotic agent, tyrosine kinase inhibitor, other
By end user: hospital and clinic, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The global idiopathic pulmonary fibrosis market report offers detailed information on several market vendors, including Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cipla Limited, FibroGen Inc., Horizon Therapeutics Public Limited Company, Jubilant Pharma Limited, MediciNova Inc., Merck & Co. Inc., Roche Holding AG, United Therapeutics Corporation, among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.
Scope of the Report
- To analyze and forecast the market size of the global idiopathic pulmonary fibrosis market.
- To classify and forecast the global idiopathic pulmonary fibrosis market based on drug type, action mode, end user, region.
- To identify drivers and challenges for the global idiopathic pulmonary fibrosis market.
- To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global idiopathic pulmonary fibrosis market.
- To identify and analyze the profile of leading players operating in the global idiopathic pulmonary fibrosis market.
Why Choose This Report
- Gain a reliable outlook of the global idiopathic pulmonary fibrosis market forecasts from 2022 to 2028 across scenarios.
- Identify growth segments for investment.
- Stay ahead of competitors through company profiles and market data.
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.
TABLE OF CONTENTS
FIGURES AND TABLES
PART 1. INTRODUCTION
· Report description
· Objectives of the study
· Market segment
· Years considered for the report
· Currency
· Key target audience
PART 2. METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
· Introduction
· Drivers
· Restraints
· Impact of COVID-19 pandemic
PART 5. MARKET BREAKDOWN BY DRUG TYPE
· Nintedanib
· Pirfenidone
· Others
PART 6. MARKET BREAKDOWN BY ACTION MODE
· Antifibrotic agent
· Tyrosine kinase inhibitor
· Other
PART 7. MARKET BREAKDOWN BY END USER
· Hospital and clinic
· Others
PART 8. MARKET BREAKDOWN BY REGION
· North America
· Europe
· Asia-Pacific
· MEA (Middle East and Africa)
· Latin America
PART 9. KEY COMPANIES
· Boehringer Ingelheim International GmbH
· Bristol Myers Squibb Company
· Cipla Limited
· FibroGen Inc.
· Horizon Therapeutics Public Limited Company
· Jubilant Pharma Limited
· MediciNova Inc.
· Merck & Co. Inc.
· Roche Holding AG
· United Therapeutics Corporation
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER
Executive Summary
Azoth Analytics has released a research report titled "Cystic Fibrosis Lung Disease Market (2024 Edition)" which provides a complete analysis of the global Cystic Fibrosis Lung Disease industry in terms of market segmentation by Drug Type (CFTR Modulators, Bronchodilat...
The global Chronic Idiopathic Myelofibrosis market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market pla...
The global Pulmonary Alveolar Proteinosis (PAP) market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market...
The global Pulmonary Drugs market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this fiel...
The global Idiopathic Pulmonary Fibrosis Drug market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market p...
The global Anti-Fibrotic Therapy for Ocular Fibrosis market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help m...
The global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact whic...
The global Cystic Fibrosis Diagnostic Tests market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market pla...
Overview of the Global Pulmonary Support Solutions Market:
The report discusses everything a marketer requires before investing in the global Pulmonary Support Solutions Market during the forecast period 2023-2030. ...
The global Kidney Fibrosis Treatment market is expected to reach US$ XX Million by 2028, with a CAGR of XX% from 2023 to 2028, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in...